Oramed Pharmaceuticals Inc. (ORMP) · Insider trading
What Oramed Pharmaceuticals's directors, officers and largest holders bought and sold themselves, from the Form 4 each of them files with the SEC within two business days of a trade. Open-market purchases and sales first: those are the trades somebody chose to make at the market price.
Bought, 12 months
$0
0 insiders, 0 trades
Sold, 12 months
$1.17M
2 insiders, 19% under a plan
Net, 12 months
−$1.17M
bought less sold
Latest filing
2026-10-02
filings read to 2026-10-19
Who traded, two years
| Insider | Bought | Sold | Trades | Last trade | Holds after |
|---|---|---|---|---|---|
| Hexter JoshuaCOO & CBO | – | $746,350 | 2 | 2026-10-01 | 1,328,130 |
| Gabay AvrahamChief Financial Officer | – | $421,054 | 2 | 2026-10-01 | 861,076 |
Open-market purchases and sales
Newest first. “Plan” marks a trade made under a 10b5-1 plan set up in advance.
| Date | Insider | Trade | Shares | Price | Value | Holds after | Filing |
|---|---|---|---|---|---|---|---|
| 2026-10-01 | Hexter JoshuaCOO & CBO | Saleplan | 30,000 | 4.51 | $135,330 | 1,328,130 | Form 4 |
| 2026-10-01 | Gabay AvrahamChief Financial Officer | Saleplan | 20,000 | 4.51 | $90,200 | 861,076 | Form 4 |
| 2026-07-01 | Gabay AvrahamChief Financial Officer | Sale | 73,360 | 4.51 | $330,854 | 671,785 | Form 4 |
| 2026-07-01 | Hexter JoshuaCOO & CBO | Sale | 137,000 | 4.46 | $611,020 | 1,023,384 | Form 4 |
Grants, exercises and other transactions
Pay, tax and paperwork rather than a choice to trade at the market price. Two years.
56 × grant or award5 × option exercise2 × shares withheld for tax2 × gift
Show them
| Date | Insider | What | Shares | Price | Holds after | Filing |
|---|---|---|---|---|---|---|
| 2026-09-24 | Gabay AvrahamChief Financial Officer | Grant or award A | +209,291 | – | 881,076 | Form 4 |
| 2026-09-24 | Kidron MiriamDirector, Chief Scientific Officer | Grant or award A | +208,125 | – | 1,341,263 | Form 4 |
| 2026-09-24 | Kidron MiriamDirector, Chief Scientific Officer | Grant or award A | +209,291 | – | 1,550,554 | Form 4 |
| 2026-09-24 | Hexter JoshuaCOO & CBO | Grant or award A | +75,455 | – | 1,148,839 | Form 4 |
| 2026-09-24 | Hexter JoshuaCOO & CBO | Grant or award A | +209,291 | – | 1,358,130 | Form 4 |
| 2026-09-24 | Kidron NadavDirector, President and CEO | Grant or award A | +349,497 | – | 3,771,740 | Form 4 |
| 2026-09-24 | Kidron NadavDirector, President and CEO | Grant or award A | +368,765 | – | 4,140,505 | Form 4 |
| 2026-07-02 | Hexter JoshuaCOO & CBO | Option exercise M | +50,000 | 3.69 | 1,073,384 | Form 4 |
| 2026-03-30 | Kidron MiriamDirector, Chief Scientific Officer | Shares withheld for tax F | −435,084 | 3.31 | 1,133,138 | Form 4 |
| 2026-03-30 | Kidron NadavDirector, President and CEO | Shares withheld for tax F | −44,818 | 3.31 | 3,422,243 | Form 4 |
| 2026-03-17 | Gabay AvrahamChief Financial Officer | Grant or award A | +95,889 | – | 745,145 | Form 4 |
| 2026-03-17 | Hexter JoshuaCOO & CBO | Grant or award A | +95,889 | – | 1,160,384 | Form 4 |
| 2026-03-17 | Kidron NadavDirector, President and CEO | Grant or award A | +167,005 | – | 3,422,243 | Form 4 |
| 2026-03-17 | Kidron MiriamDirector, Chief Scientific Officer | Grant or award A | +119,558 | – | 1,568,222 | Form 4 |
| 2026-03-12 | Kidron NadavDirector, President and CEO | Gift G | −100,000 | – | 3,255,238 | Form 4 |
| 2026-01-22 | Gabay AvrahamChief Financial Officer | Option exercise M | +19,000 | – | 649,256 | Form 4 |
| 2026-01-22 | Hexter JoshuaCOO & CBO | Option exercise M | +19,000 | – | 1,064,495 | Form 4 |
| 2026-01-22 | Kidron MiriamDirector, Chief Scientific Officer | Option exercise M | +19,000 | – | 1,448,664 | Form 4 |
| 2026-01-22 | Kidron NadavDirector, President and CEO | Option exercise M | +109,000 | – | 3,355,238 | Form 4 |
| 2026-01-14 | Kidron MiriamDirector, Chief Scientific Officer | Gift G | −86,166 | – | 1,343,498 | Form 4 |
| 2025-12-31 | Mayer ArieDirector | Grant or award A | +30,000 | – | 163,109 | Form 4 |
| 2025-12-31 | Mayer ArieDirector | Grant or award A | +4,900 | – | 168,009 | Form 4 |
| 2025-12-31 | Shapiro BenjaminDirector | Grant or award A | +30,000 | – | 119,720 | Form 4 |
| 2025-12-31 | Shapiro BenjaminDirector | Grant or award A | +3,500 | – | 123,220 | Form 4 |
| 2025-12-31 | Hexter JoshuaCOO & CBO | Grant or award A | +97,328 | – | 930,495 | Form 4 |
| 2025-12-31 | Hexter JoshuaCOO & CBO | Grant or award A | +115,000 | – | 1,045,495 | Form 4 |
| 2025-12-31 | Kidron MiriamDirector, Chief Scientific Officer | Grant or award A | +121,331 | – | 1,314,664 | Form 4 |
| 2025-12-31 | Kidron MiriamDirector, Chief Scientific Officer | Grant or award A | +115,000 | – | 1,429,664 | Form 4 |
| 2025-12-31 | Kidron NadavDirector, President and CEO | Grant or award A | +232,640 | – | 2,919,238 | Form 4 |
| 2025-12-31 | Kidron NadavDirector, President and CEO | Grant or award A | +327,000 | – | 3,246,238 | Form 4 |
| 2025-12-31 | Reznick YehudaDirector | Grant or award A | +30,000 | – | 98,930 | Form 4 |
| 2025-12-31 | Reznick YehudaDirector | Grant or award A | +6,250 | – | 105,180 | Form 4 |
| 2025-12-31 | Gabay AvrahamChief Financial Officer | Grant or award A | +81,216 | – | 515,256 | Form 4 |
| 2025-12-31 | Gabay AvrahamChief Financial Officer | Grant or award A | +115,000 | – | 630,256 | Form 4 |
| 2025-12-31 | Aghion DanielDirector | Grant or award A | +30,000 | – | 107,191 | Form 4 |
| 2025-12-31 | Aghion DanielDirector | Grant or award A | +6,250 | – | 113,441 | Form 4 |
| 2025-06-05 | Shapiro BenjaminDirector | Grant or award A | +30,000 | – | 85,070 | Form 4 |
| 2025-06-05 | Shapiro BenjaminDirector | Grant or award A | +4,650 | – | 89,720 | Form 4 |
| 2025-06-05 | Sank LeonardDirector | Grant or award A | +30,000 | – | 128,021 | Form 4 |
| 2025-06-05 | Sank LeonardDirector | Grant or award A | +6,510 | – | 134,531 | Form 4 |
| 2025-06-05 | Reznick YehudaDirector | Grant or award A | +30,000 | – | 60,560 | Form 4 |
| 2025-06-05 | Reznick YehudaDirector | Grant or award A | +8,370 | – | 68,930 | Form 4 |
| 2025-06-05 | Aghion DanielDirector | Grant or award A | +30,000 | – | 68,820 | Form 4 |
| 2025-06-05 | Aghion DanielDirector | Grant or award A | +8,371 | – | 77,191 | Form 4 |
| 2025-06-05 | Mayer ArieDirector | Grant or award A | +30,000 | – | 126,134 | Form 4 |
| 2025-06-05 | Mayer ArieDirector | Grant or award A | +6,975 | – | 133,109 | Form 4 |
| 2025-02-11 | Gabay AvrahamChief Financial Officer | Grant or award A | +34,000 | – | 392,040 | Form 4 |
| 2025-02-11 | Gabay AvrahamChief Financial Officer | Grant or award A | +42,000 | – | 434,040 | Form 4 |
| 2025-02-11 | Kidron NadavDirector, President and CEO | Grant or award A | +141,000 | – | 2,400,598 | Form 4 |
| 2025-02-11 | Kidron NadavDirector, President and CEO | Grant or award A | +186,000 | – | 2,586,598 | Form 4 |
| 2025-02-11 | Kidron NadavDirector, President and CEO | Grant or award A | +100,000 | – | 2,686,598 | Form 4 |
| 2025-02-11 | Hexter JoshuaCOO & CBO | Grant or award A | +45,000 | – | 751,333 | Form 4 |
| 2025-02-11 | Hexter JoshuaCOO & CBO | Grant or award A | +48,500 | – | 799,833 | Form 4 |
| 2025-02-11 | Hexter JoshuaCOO & CBO | Grant or award A | +33,334 | – | 833,167 | Form 4 |
| 2025-02-11 | Kidron MiriamDirector, Chief Scientific Officer | Grant or award A | +74,000 | – | 1,074,666 | Form 4 |
| 2025-02-11 | Kidron MiriamDirector, Chief Scientific Officer | Grant or award A | +52,000 | – | 1,126,666 | Form 4 |
| 2025-02-11 | Kidron MiriamDirector, Chief Scientific Officer | Grant or award A | +66,667 | – | 1,193,333 | Form 4 |
| 2025-01-02 | Hexter JoshuaCOO & CBO | Grant or award A | +194,500 | – | 706,333 | Form 4 |
| 2025-01-02 | Gabay AvrahamChief Financial Officer | Grant or award A | +188,000 | – | 358,040 | Form 4 |
| 2025-01-02 | Kidron NadavDirector, President and CEO | Grant or award A | +433,500 | – | 2,259,598 | Form 4 |
| 2025-01-02 | Kidron MiriamDirector, Chief Scientific Officer | Grant or award A | +207,000 | – | 1,000,666 | Form 4 |
| 2024-11-07 | Hexter JoshuaCOO & CBO | Grant or award A | +30,000 | – | 511,833 | Form 4 |
| 2024-11-07 | Kidron MiriamChief Scientific Officer | Grant or award A | +30,000 | – | 793,666 | Form 4 |
| 2024-11-07 | Kidron NadavDirector, President and CEO | Grant or award A | +45,000 | – | 1,826,098 | Form 4 |
| 2024-11-07 | Gabay AvrahamChief Financial Officer | Grant or award A | +30,000 | – | 170,040 | Form 4 |
How to read it
- Buy, sale
- Code P and S on the form: shares bought or sold in the market, at the market price. The other codes are mostly pay (a grant, an option exercised) or tax (shares the company withheld), and say little about what the insider thinks of the price.
- Plan
- A sale or purchase under a Rule 10b5-1 plan, set up in advance and running on its own schedule. Since April 2023 the form has a box for it. Much executive selling is planned and says more about diversifying than about the company.
- Holds after
- The shares the insider still held after the trade, in the form the trade was in (directly, or indirectly through a trust or a fund).
- Value
- Shares times the price the form reports, which is often an average over several fills on the day.
Read from the SEC's own quarterly data sets of Forms 3, 4 and 5, and from each day's filings since the last one. A correcting amendment replaces the lines it restates. Every row links to its filing. None of this is advice: insiders sell for many reasons, and buy for fewer.